Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age
Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age
Cork MJ, Deleuran M, Geng B, et al. J Allergy Clin Immunol Pract. 2025;13(5):1164-1175.e2. doi:10.1016/j.jaip.2025.02.040
Introduction
Abrocitinib, a Janus kinase (JAK) inhibitor, has been increasingly utilized in patients with moderate-to-severe atopic dermatitis (AD), a chronic inflammatory skin condition with significant morbidity. Long-term safety data are crucial in this population, given the need for sustained treatment and the potential for cumulative or age-related adverse effects. Understanding how the safety profile of abrocitinib varies across different age groups helps inform personalized treatment decisions and dose selection, especially in vulnerable populations such as adolescents and the elderly.
This integrated analysis pooled data from multiple JADE clinical trials to evaluate the long-term safety outcomes of abrocitinib by age, with a particular focus on treatment-emergent adverse events (TEAEs) of special interest that may impact clinical management and patient monitoring.
Study Overview
Study Design: Integrated post hoc analysis pooling data from JADE Phase 2 and Phase 3 clinical trials, including long-term extension studies, with data cutoff Sept 25, 2021.
Population: 3,802 patients with moderate-to-severe atopic dermatitis, categorized by age groups: adolescents (12 to <18 years), 18 to <40 years, 40 to <65 years, and 65+ years.
Intervention: Abrocitinib administered at consistent doses (100 mg or 200 mg) or variable dosing regimens, including 12-week induction with 200 mg followed by randomized maintenance dose or placebo.
Outcomes: Incidence rates of treatment-emergent adverse events (TEAEs) of special interest, including serious adverse events, infections, malignancies, and cardiovascular events, stratified by age.
Key Findings
Comprehensive Results and Analysis
- The integrated cohort included 3,802 patients with 5,214 patient-years of abrocitinib exposure.
- Patients aged 65 years or older had consistently higher incidence rates of TEAEs of special interest compared to younger groups.
- These TEAEs with increased incidence in older adults included serious adverse events, drug discontinuations due to adverse events, serious infections, herpes zoster, thrombocytopenia, lymphopenia, nonmelanoma skin cancer, other malignancies, major cardiovascular events, and venous thromboembolism.
- Adolescent patients (12 to <18 years) exhibited the lowest incidence rates across these key adverse event categories.
- Findings emphasize the need for careful dose optimization in elderly patients to balance efficacy and safety risks.
Evidence Synthesis
The present analysis aligns closely with emerging safety data within the abrocitinib clinical trial program and complements existing literature on age-specific safety profiles in moderate-to-severe atopic dermatitis treatments.
Supporting Studies
- Valdez et al., 2024: Integrated safety update corroborated higher rates of serious adverse events and infections in patients aged 65 years and reinforced the favorable safety profile of abrocitinib overall. (Am J Clin Dermatol. 25(4):639-654; PMID: 38888681)
- Paller et al., 2025: Focused integrated analysis confirmed adolescents demonstrated the lowest adverse event incidence, supporting the age-related differential safety profile (Allergy. DOI: 10.1111/all.15933; PMID: 40028832).
Summary Table of Key Age-Related Safety Findings
| Adverse Event Category | Incidence Trend by Age Group |
|---|---|
| Serious Adverse Events | Increasing incidence from adolescents to oldest age group; highest in 65 years |
| Discontinuations due to TEAEs | Higher rates in elderly patients (65 years) than younger groups |
| Serious Infections | Numerically elevated in patients 65 years |
| Herpes Zoster | Notably more common in older adults |
| Hematologic Abnormalities (Thrombocytopenia, Lymphopenia) | Higher rates observed in elderly cohort |
| Malignancies (NMSC & others) | Increased incidence in the 65+ age bracket |
| Major Cardiovascular Events & Venous Thromboembolism | Elevated in elderly patients compared to younger cohorts |
This body of evidence emphasizes an age-related differential safety profile for abrocitinib, lending further weight to clinical decisions that incorporate age and comorbidity considerations for dosing strategies.
Clinical Implications
- Clinicians should consider age as a critical factor when initiating or adjusting abrocitinib treatment, especially in patients aged 65 years or older.
- Lower incidence of TEAEs in adolescents supports use of abrocitinib as a safe long-term option in this population with appropriate monitoring.
- Close monitoring for infections, malignancies, and hematologic abnormalities is recommended in older adults to promptly identify and manage adverse events.
- Dose selection should be cautious in elderly patients, with emphasis on balancing efficacy against increased risk for serious adverse events.
Strengths & Limitations
| Strengths | Limitations |
|---|---|
| Large integrated cohort of 3,802 patients with 5,214 patient-years exposure allowing robust safety analysis. | Post hoc nature of age subgroup analyses; findings warrant prospective validation. |
| Comprehensive age stratification including adolescents and elderly for detailed safety profiling. | Potential underrepresentation of the oldest and most frail elderly patients limiting generalizability. |
| Consistency with other published integrated analyses enhances external validity. | Lack of direct comparisons with other JAK inhibitors or biologic agents limits contextual application. |
| Use of standardized definitions for TEAEs of special interest across trials. | Data cutoff date restricts inclusion of newer safety signals or real-world postmarketing data. |
Future Directions
Future research should include direct comparative studies between abrocitinib and other JAK inhibitors or biologics with age stratification to clarify relative safety profiles. Additionally, mechanistic studies exploring the biological basis of age-related differences in adverse event susceptibility could guide personalized therapeutic approaches.
Conclusion
Abrocitinib maintains a manageable long-term safety profile for moderate-to-severe atopic dermatitis, with adolescents experiencing fewer adverse events and elderly patients demonstrating higher risks, underscoring the importance of age-informed dose selection.
Listen to the Podcast
A short discussion of today’s highlight.
References
- Valdez H, Fan H, Farooqui SA, et al. Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate or Severe Atopic Dermatitis. Am J Clin Dermatol. 2024;25(4):639-654. doi:10.1007/s40257-024-00869-7. PMID: 38888681.
- Paller AS, Eichenfield LF, Irvine AD, et al. Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis. Allergy. 2025 Mar 3. doi:10.1111/all.15933. Epub ahead of print. PMID: 40028832.
